Innoviva Inc.

AI Score

XX

Unlock

18.27
0.18 (1.00%)
At close: Apr 17, 2025, 3:59 PM
18.27
0.00%
After-hours: Apr 17, 2025, 04:20 PM EDT
1.00%
Bid 16
Market Cap 1.15B
Revenue (ttm) 365.62M
Net Income (ttm) 23.39M
EPS (ttm) 0.36
PE Ratio (ttm) 50.75
Forward PE 10.5
Analyst Buy
Ask 18.5
Volume 737,456
Avg. Volume (20D) 828,977
Open 18.20
Previous Close 18.09
Day's Range 18.16 - 18.38
52-Week Range 14.69 - 21.28
Beta 0.49

About INVA

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 5, 2004
Employees 127
Stock Exchange NASDAQ
Ticker Symbol INVA
Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for INVA stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 201.04% from the latest price.

Stock Forecasts

Next Earnings Release

Innoviva Inc. is scheduled to release its earnings on May 7, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription